Buoyed by strong first quarter results and a spate of new and expected product launches, Eli Lilly and Co. (NYSE: LLY) Chief Executive Officer Dave Ricks is speaking with optimism about the company’s outlook. Lilly raised its full-year 2018 revenue guidance and earnings-per-share expectations after reporting first quarter results that showed profits surging to $1.2 billion. However, Ricks says it’s the quality behind the numbers that gives him reason for optimism, noting that nine new products have been launched since the end of 2014, with six more in the pipeline.
"This is the kind of research and development productivity we haven’t seen in our history and will be unprecedented for a company our size," said Ricks. "These products will last a long time… I think we’ve got a bright period ahead."
In an interview for Inside INdiana Business with Gerry Dick, Ricks talked about keys for future success.
Ricks made the remarks after announcing a five-year, $7 million initiative aimed at addressing the high incidence of diabetes in Indiana. Lilly is partnering with the Richard M. Fairbanks School of Public Health at IUPUI on the effort, which will focus on three Indianapolis neighborhoods that Lilly says have significant health disparities and high rates of diabetes. The program builds on similar efforts Lilly has implemented in countries including Mexico, India and South Africa.